Addressing	O
the	O
Crisis	B:C0231224
in	O
the	O
Treatment	O
of	O
Osteoporosis	O
:	O
A	O
Path	O
Forward	O
.	O

Addressing	O
the	O
Crisis	O
in	O
the	O
Treatment	B:C0087111
of	O
Osteoporosis	O
:	O
A	O
Path	O
Forward	O
.	O

Addressing	O
the	O
Crisis	O
in	O
the	O
Treatment	O
of	O
Osteoporosis	B:C0029456
:	O
A	O
Path	O
Forward	O
.	O

Considerable	O
data	O
and	O
media	B:C0009458
attention	O
have	O
highlighted	O
a	O
potential	O
"	O
crisis	O
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
.	O

Considerable	O
data	O
and	O
media	O
attention	B:C0004268
have	O
highlighted	O
a	O
potential	O
"	O
crisis	O
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
.	O

Considerable	O
data	O
and	O
media	O
attention	O
have	O
highlighted	O
a	O
potential	O
"	O
crisis	B:C0231224
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
.	O

Considerable	O
data	O
and	O
media	O
attention	O
have	O
highlighted	O
a	O
potential	O
"	O
crisis	O
"	O
in	O
the	O
treatment	B:C0087111
of	O
osteoporosis	O
.	O

Considerable	O
data	O
and	O
media	O
attention	O
have	O
highlighted	O
a	O
potential	O
"	O
crisis	O
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	B:C0029456
.	O

Specifically	O
,	O
despite	O
the	O
availability	O
of	O
several	O
effective	O
drugs	B:C0013227
to	O
prevent	O
fractures	O
,	O
many	O
patients	O
who	O
need	O
pharmacological	O
therapy	I:C0013216
are	O
either	O
not	O
being	O
prescribed	O
these	O
medications	O
or	O
if	O
prescribed	O
a	O
medication	O
,	O
are	O
simply	O
not	O
taking	O
it	O
.	O

Specifically	O
,	O
despite	O
the	O
availability	O
of	O
several	O
effective	O
drugs	O
to	O
prevent	O
fractures	B:C0016658
,	O
many	O
patients	O
who	O
need	O
pharmacological	O
therapy	I:C0013216
are	O
either	O
not	O
being	O
prescribed	O
these	O
medications	O
or	O
if	O
prescribed	O
a	O
medication	O
,	O
are	O
simply	O
not	O
taking	O
it	O
.	O

Specifically	O
,	O
despite	O
the	O
availability	O
of	O
several	O
effective	O
drugs	O
to	O
prevent	O
fractures	O
,	O
many	O
patients	O
who	O
need	O
pharmacological	B:C0013216
therapy	I:C0013216
are	O
either	O
not	O
being	O
prescribed	O
these	O
medications	O
or	O
if	O
prescribed	O
a	O
medication	O
,	O
are	O
simply	O
not	O
taking	O
it	O
.	O

Specifically	O
,	O
despite	O
the	O
availability	O
of	O
several	O
effective	O
drugs	O
to	O
prevent	O
fractures	O
,	O
many	O
patients	O
who	O
need	O
pharmacological	O
therapy	I:C0013216
are	O
either	O
not	O
being	O
prescribed	O
these	O
medications	B:C0013227
or	O
if	O
prescribed	O
a	O
medication	O
,	O
are	O
simply	O
not	O
taking	O
it	O
.	O

Specifically	O
,	O
despite	O
the	O
availability	O
of	O
several	O
effective	O
drugs	O
to	O
prevent	O
fractures	O
,	O
many	O
patients	O
who	O
need	O
pharmacological	O
therapy	I:C0013216
are	O
either	O
not	O
being	O
prescribed	O
these	O
medications	O
or	O
if	O
prescribed	O
a	O
medication	B:C0013227
,	O
are	O
simply	O
not	O
taking	O
it	O
.	O

Although	O
there	O
are	O
many	O
reasons	O
for	O
this	O
"	O
gap	O
"	O
in	O
the	O
treatment	B:C0087111
of	O
osteoporosis	O
,	O
a	O
major	O
factor	O
is	O
physician	O
and	O
patient	O
concerns	O
over	O
the	O
risk	O
of	O
side	O
effects	I:C0879626
,	O
especially	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
(	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
)	O
related	O
to	O
bisphosphonate	O
(	O
and	O
perhaps	O
other	O
antiresorptive	O
)	O
drug	O
therapy	I:C0013216
.	O

Although	O
there	O
are	O
many	O
reasons	O
for	O
this	O
"	O
gap	O
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	B:C0029456
,	O
a	O
major	O
factor	O
is	O
physician	O
and	O
patient	O
concerns	O
over	O
the	O
risk	O
of	O
side	O
effects	I:C0879626
,	O
especially	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
(	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
)	O
related	O
to	O
bisphosphonate	O
(	O
and	O
perhaps	O
other	O
antiresorptive	O
)	O
drug	O
therapy	I:C0013216
.	O

Although	O
there	O
are	O
many	O
reasons	O
for	O
this	O
"	O
gap	O
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
,	O
a	O
major	O
factor	O
is	O
physician	B:C0031831
and	O
patient	O
concerns	O
over	O
the	O
risk	O
of	O
side	O
effects	I:C0879626
,	O
especially	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
(	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
)	O
related	O
to	O
bisphosphonate	O
(	O
and	O
perhaps	O
other	O
antiresorptive	O
)	O
drug	O
therapy	I:C0013216
.	O

Although	O
there	O
are	O
many	O
reasons	O
for	O
this	O
"	O
gap	O
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
,	O
a	O
major	O
factor	O
is	O
physician	O
and	O
patient	O
concerns	O
over	O
the	O
risk	O
of	O
side	B:C0879626
effects	I:C0879626
,	O
especially	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
(	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
)	O
related	O
to	O
bisphosphonate	O
(	O
and	O
perhaps	O
other	O
antiresorptive	O
)	O
drug	O
therapy	I:C0013216
.	O

Although	O
there	O
are	O
many	O
reasons	O
for	O
this	O
"	O
gap	O
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
,	O
a	O
major	O
factor	O
is	O
physician	O
and	O
patient	O
concerns	O
over	O
the	O
risk	O
of	O
side	O
effects	I:C0879626
,	O
especially	O
atypical	B:C3160754
femur	I:C3160754
fractures	I:C3160754
(	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
)	O
related	O
to	O
bisphosphonate	O
(	O
and	O
perhaps	O
other	O
antiresorptive	O
)	O
drug	O
therapy	I:C0013216
.	O

Although	O
there	O
are	O
many	O
reasons	O
for	O
this	O
"	O
gap	O
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
,	O
a	O
major	O
factor	O
is	O
physician	O
and	O
patient	O
concerns	O
over	O
the	O
risk	O
of	O
side	O
effects	I:C0879626
,	O
especially	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
(	O
atypical	B:C3160754
femur	I:C3160754
fractures	I:C3160754
)	O
related	O
to	O
bisphosphonate	O
(	O
and	O
perhaps	O
other	O
antiresorptive	O
)	O
drug	O
therapy	I:C0013216
.	O

Although	O
there	O
are	O
many	O
reasons	O
for	O
this	O
"	O
gap	O
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
,	O
a	O
major	O
factor	O
is	O
physician	O
and	O
patient	O
concerns	O
over	O
the	O
risk	O
of	O
side	O
effects	I:C0879626
,	O
especially	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
(	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
)	O
related	O
to	O
bisphosphonate	B:C2267018
(	O
and	O
perhaps	O
other	O
antiresorptive	O
)	O
drug	O
therapy	I:C0013216
.	O

Although	O
there	O
are	O
many	O
reasons	O
for	O
this	O
"	O
gap	O
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
,	O
a	O
major	O
factor	O
is	O
physician	O
and	O
patient	O
concerns	O
over	O
the	O
risk	O
of	O
side	O
effects	I:C0879626
,	O
especially	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
(	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
)	O
related	O
to	O
bisphosphonate	O
(	O
and	O
perhaps	O
other	O
antiresorptive	B:C0521941
)	O
drug	O
therapy	I:C0013216
.	O

Although	O
there	O
are	O
many	O
reasons	O
for	O
this	O
"	O
gap	O
"	O
in	O
the	O
treatment	O
of	O
osteoporosis	O
,	O
a	O
major	O
factor	O
is	O
physician	O
and	O
patient	O
concerns	O
over	O
the	O
risk	O
of	O
side	O
effects	I:C0879626
,	O
especially	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
(	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
)	O
related	O
to	O
bisphosphonate	O
(	O
and	O
perhaps	O
other	O
antiresorptive	O
)	O
drug	B:C0013216
therapy	I:C0013216
.	O

In	O
this	O
perspective	O
,	O
we	O
review	O
the	O
current	O
state	O
of	O
undertreatment	O
of	O
patients	O
at	O
increased	O
fracture	B:C0016658
risk	O
and	O
suggest	O
possible	O
short	O
-	O
,	O
intermediate	O
-	I:C0205103
,	O
and	O
long	O
-	O
term	O
approaches	O
to	O
address	O
patient	O
concerns	O
,	O
specifically	O
those	O
related	O
to	O
AFF	O
risk	O
.	O

In	O
this	O
perspective	O
,	O
we	O
review	O
the	O
current	O
state	O
of	O
undertreatment	O
of	O
patients	O
at	O
increased	O
fracture	O
risk	O
and	O
suggest	O
possible	O
short	O
-	O
,	O
intermediate	B:C0205103
-	I:C0205103
,	O
and	O
long	O
-	O
term	O
approaches	O
to	O
address	O
patient	O
concerns	O
,	O
specifically	O
those	O
related	O
to	O
AFF	O
risk	O
.	O

In	O
this	O
perspective	O
,	O
we	O
review	O
the	O
current	O
state	O
of	O
undertreatment	O
of	O
patients	O
at	O
increased	O
fracture	O
risk	O
and	O
suggest	O
possible	O
short	O
-	O
,	O
intermediate	O
-	I:C0205103
,	O
and	O
long	O
-	O
term	O
approaches	B:C0449445
to	O
address	O
patient	O
concerns	O
,	O
specifically	O
those	O
related	O
to	O
AFF	O
risk	O
.	O

In	O
this	O
perspective	O
,	O
we	O
review	O
the	O
current	O
state	O
of	O
undertreatment	O
of	O
patients	O
at	O
increased	O
fracture	O
risk	O
and	O
suggest	O
possible	O
short	O
-	O
,	O
intermediate	O
-	I:C0205103
,	O
and	O
long	O
-	O
term	O
approaches	O
to	O
address	O
patient	O
concerns	O
,	O
specifically	O
those	O
related	O
to	O
AFF	B:C3160754
risk	O
.	O

We	O
suggest	O
improved	B:C0184511
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	B:C0031831
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	B:C0013622
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	B:C3494358
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	B:C0015811
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	B:C0441633
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	B:C1510486
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	B:C1510486
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	B:C0030695
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	B:C0521941
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	B:C0087111
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	B:C1510486
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	B:C0035648
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	O
to	O
identify	O
risk	O
markers	O
.	O

We	O
suggest	O
improved	O
patient	O
and	O
physician	O
education	O
on	O
prodromal	O
symptoms	I:C3494358
,	O
extended	O
femur	O
scans	O
using	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
(	O
dual	O
-	I:C1510486
energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
)	O
to	O
monitor	O
patients	I:C0030695
on	O
antiresorptive	O
treatment	O
,	O
better	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
perhaps	O
using	O
geometrical	O
parameters	O
from	O
dual	O
-	I:C1510486
energy	I:C1510486
X	I:C1510486
-	I:C1510486
ray	I:C1510486
absorptiometry	I:C1510486
and	O
other	O
risk	O
factors	I:C0035648
,	O
and	O
more	O
research	O
on	O
pharmacogenomics	B:C1138555
to	O
identify	O
risk	O
markers	O
.	O

Although	O
not	O
the	O
only	O
impediment	O
to	O
appropriate	O
treatment	B:C0087111
of	O
osteoporosis	O
,	O
concern	O
over	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
remains	O
a	O
major	O
issue	O
and	O
one	O
that	O
needs	O
to	O
be	O
resolved	O
for	O
effective	O
dissemination	O
of	O
existing	O
treatments	O
to	O
reduce	O
fracture	O
risk	O
.	O

Although	O
not	O
the	O
only	O
impediment	O
to	O
appropriate	O
treatment	O
of	O
osteoporosis	B:C0029456
,	O
concern	O
over	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
remains	O
a	O
major	O
issue	O
and	O
one	O
that	O
needs	O
to	O
be	O
resolved	O
for	O
effective	O
dissemination	O
of	O
existing	O
treatments	O
to	O
reduce	O
fracture	O
risk	O
.	O

Although	O
not	O
the	O
only	O
impediment	O
to	O
appropriate	O
treatment	O
of	O
osteoporosis	O
,	O
concern	O
over	O
atypical	B:C3160754
femur	I:C3160754
fractures	I:C3160754
remains	O
a	O
major	O
issue	O
and	O
one	O
that	O
needs	O
to	O
be	O
resolved	O
for	O
effective	O
dissemination	O
of	O
existing	O
treatments	O
to	O
reduce	O
fracture	O
risk	O
.	O

Although	O
not	O
the	O
only	O
impediment	O
to	O
appropriate	O
treatment	O
of	O
osteoporosis	O
,	O
concern	O
over	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
remains	O
a	O
major	O
issue	B:C0033213
and	O
one	O
that	O
needs	O
to	O
be	O
resolved	O
for	O
effective	O
dissemination	O
of	O
existing	O
treatments	O
to	O
reduce	O
fracture	O
risk	O
.	O

Although	O
not	O
the	O
only	O
impediment	O
to	O
appropriate	O
treatment	O
of	O
osteoporosis	O
,	O
concern	O
over	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
remains	O
a	O
major	O
issue	O
and	O
one	O
that	O
needs	O
to	O
be	O
resolved	B:C3714811
for	O
effective	O
dissemination	O
of	O
existing	O
treatments	O
to	O
reduce	O
fracture	O
risk	O
.	O

Although	O
not	O
the	O
only	O
impediment	O
to	O
appropriate	O
treatment	O
of	O
osteoporosis	O
,	O
concern	O
over	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
remains	O
a	O
major	O
issue	O
and	O
one	O
that	O
needs	O
to	O
be	O
resolved	O
for	O
effective	O
dissemination	B:C0205221
of	O
existing	O
treatments	O
to	O
reduce	O
fracture	O
risk	O
.	O

Although	O
not	O
the	O
only	O
impediment	O
to	O
appropriate	O
treatment	O
of	O
osteoporosis	O
,	O
concern	O
over	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
remains	O
a	O
major	O
issue	O
and	O
one	O
that	O
needs	O
to	O
be	O
resolved	O
for	O
effective	O
dissemination	O
of	O
existing	O
treatments	B:C0087111
to	O
reduce	O
fracture	O
risk	O
.	O

Although	O
not	O
the	O
only	O
impediment	O
to	O
appropriate	O
treatment	O
of	O
osteoporosis	O
,	O
concern	O
over	O
atypical	O
femur	I:C3160754
fractures	I:C3160754
remains	O
a	O
major	O
issue	O
and	O
one	O
that	O
needs	O
to	O
be	O
resolved	O
for	O
effective	O
dissemination	O
of	O
existing	O
treatments	O
to	O
reduce	O
fracture	B:C0016658
risk	O
.	O

